Table 5 Clinical characteristics in BRCA-mutated and BRCA-negative groups. Patients with unknown BRCA status were excluded from the current analysis
Characteristic | BRCA-mutated | BRCA-negative | p |
|---|---|---|---|
Total, n | 26 | 49 | |
BRCA1 | 25 | NA | |
BRCA2 | 1 | NA | |
Age, years | 0.017 | ||
Range | 33–80 | 26–71 | |
Mean | 44 | 55 | |
95% CI | 36.8–48.5 | 48–60 | |
Ki67 score, % | 0.621 | ||
Range | 5–87 | 10–90 | |
Mean | 60 | 52.5 | |
95% CI | 40–60 | 39.5–60 | |
Pathological response (Miller-Payne), n (%) | 0.0139 | ||
I-II | 0 (0) | 17 (34.7) | |
III-IV | 11 (42.3) | 22 (44.9) | |
V (pCR) | 15 (57.7) | 10 (20.4) | |
Size, mm | 0.929 | ||
Range | 10–63 | 12–70 | |
Mean | 32.5 | 29 | |
95% CI | 20.1–40.4 | 25–36.3 | |
T prior to NAC, n (%) | 0.141 | ||
cT1 | 4 (15.4) | 6 (12.2) | |
cT2 | 18 (69.2) | 29 (59.2) | |
cT3 | 4 (15.4) | 8 (16.3) | |
cT4 | 0 (0) | 6 (12.3) | |
N prior to NAC, n (%) | 0.589 | ||
cN0 | 12 (46.2) | 25 (51) | |
cN1 | 9 (34.6) | 16 (32.6) | |
cN2 | 2 (7.7) | 4 (8.2) | |
cN3 | 3 (11.5) | 4 (8.2) | |
NAC regimen, n (%) | 0.0001 | ||
Platinum based | 24 (92.3) | 20 (40.8) | |
Nonplatinum based | 2 (7.7) | 29 (59.2) | |
Surgery, n (%) | 0.0001 | ||
Sectoral resection + sentinel node biopsy | 5 (19.2) | 27 (55.1) | |
Sectoral resection + lymph node excision | 0 (0) | 5 (10.2) | |
Mastectomy + sentinel node biopsy | 4 (15.4) | 9 (18.4) | |
Mastectomy + lymph node excision | 4 (15.4) | 7 (14.3) | |
Bilateral mastectomy | 13 (50) | 1 (2) |